TIBEO
LIVE

Serial Number

97785396

Owner

Jubilant Therapeutics Inc.

Attorney

Joseph V. Norvell

First Use Date

Mar 1, 2022

Filing Date

Feb 8, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TIBEO Trademark

Serial Number: 97785396

TIBEO is a trademark filed by Jubilant Therapeutics Inc. on February 8, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Jubilant Therapeutics Inc.

1430 US Highway 206, Suite 110
Bedminster, NJ 07921

Entity Type: 03

Trademark Details

Filing Date

February 8, 2023

Registration Date

Not Registered

First Use Anywhere

March 1, 2022

First Use in Commerce

March 1, 2022

Goods & Services

Scientific and medical research and development in the field of cancer and autoimmune disease research and pharmaceutical drug development; medical research laboratory services in the field of oncology and autoimmune disease, drug development, biotechnology development, drug development services; pharmaceutical drug development services in the field of oncology and autoimmune diseases; scientific research and development services in the field of cancer, oncology and autoimmune diseases; scientific research for medical purposes in the field of cancerous and autoimmune diseases; clinical research in the field of cancer, oncology and autoimmune diseases; research and development services in the field of drug development for cancer and autoimmune diseases; providing an online non-downloadable computer software platform for medical research, pharmaceutical drug discovery and pharmaceutical drug development; Pharmaceutical product research and development for cancer, oncology and autoimmune diseases; Research and development of medicines and pharmaceutical preparations for the treatment of cancer and autoimmune diseases; Scientific and technological services, namely, scientific research and development of pharmaceutical drugs for the treatment of cancer and autoimmune diseases in the field of medicine; scientific laboratory services; Testing, inspection or research of pharmaceuticals

Pharmaceutical preparations for the treatment of cancer, and autoimmune diseases

Filing History

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 30, 2026 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 12, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 11, 2025 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 10, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 26, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 29, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 29, 2024 GNSL
SUSPENSION LETTER WRITTEN
Aug 29, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 7, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 5, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 5, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 8, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 8, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 8, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 7, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 27, 2023 NWOS
NEW APPLICATION ENTERED
Feb 11, 2023 NWAP